Shalby Ltd. · NSE:SHALBY
Shalby — Q2 FY2019 Earnings Presentation
21 slides from Shalby's earnings presentation, Oct 26, 2018
Slide 1: Covering letter to stock exchanges
October 26, 2018 Shalby/SE/2018‐19/70 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, 25th Floor, Phiroze Jeejeebhoy Towers, Bandra‐Kurla Complex, Bandra (E), Dalal Street, Mumbai 400 051. Mumbai 400 001. Scr
Slide 2: Investor Presentation
SHALBY MULTI-SPECIALTY —— HOSPITALS — @ Investor Presentation
Slide 3: Important Disclosure
Important Disclosure No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its da
Slide 4: Because passion drives perfection
…because passion drives perfection… …and perfection drives performance “ 3
Slide 5: Current Scale of Operations
Current Scale of Operations 11 Hospitals 55% Operating bed to total bed capacity 2,012* Total Bed Capacity 51% Bed Occupancy (based on census beds) 1,102** Operational beds 31% 11 year CAGR Revenue 887 Census Beds 40% 11 year CAGR EBITDA 165 Non Census Beds 405 Doctors & 3,000+ Support Staff Double-
Slide 6: Performance Q2FY19
— @ > Performance Q2FY19
Slide 7: Key Achievements of the Quarter
Key Achievements of the Quarter Huge Ovarian Revenue growth Mass removed Avg. Occupied of 34% Y-o-Y and from an 11 year Beds rose by 42% EBITDA for the old girl at Shalby Y-o-YWide procedurequarter stood at penetration Jaipur – to Tier 2 and 3 cities21% 6
Slide 8: Performance Synopsis
Performance Synopsis (INR in million) Quarter Ended Quarter Ended Particulars % of Revenue % of Revenue Growth 30-09-18 30-09-17 Total Revenue 1,216.1 909.0 33.8% EBITDA 250.5 20.6% 245.5 27.0% 2.1% Bed Capacity (Nos.) 2012 2012 0% Operational Beds (Nos.) 1,102 941 17.1% Average Length of Stay(Days)
Slide 9: Financial Highlights Q2FY19 Standalone
Financial Highlights Q2FY19 Standalone (INR in million) Quarter Ended Quarter Ended Particulars 30/09/2018 % of Revenue 30/09/2017 % of Revenue Growth Revenue from Operations 1193.9 893.7 33.6% Other Income 22.2 15.3 Total Income 1216.1 909.0 33.8% Expenses Materials & Consumables 304.5 25.0% 225.5
Slide 10: Financials Parameters
Financials Parameters (INR in million) Total Revenue EBITDA 250.5 PBT 1216.1 149.0 147.0 245.5 909.0 Q2 FY18 Q2 FY19 Q2 FY18 Q2 FY19 Q2 FY18 Q2 FY19 • Total Revenue has increased by 33.8% on Year on Year basis • PBT for Q2 FY 19 has decreased by 1.3% compared to Q2 FY 18 as Depreciation has increase
Slide 11: ARPOB and ALOS
ARPOB and ALOS 31,071 29,244 3.69 2.82 Q2 FY18 Q2 FY19 ARPOB (in Rs / day) ALOS (Days) • Marginal shrink in ARPOB is due to change in specialty mix due to increased multi-specialty focus as well as current quarter witnessing epidemic resulting into high number of non-surgical procedures • Change in
Slide 12: Revenue Mix Q2FY19
Revenue Mix Q2FY19 Specialty Mix Payer Profile 4% 10% 5% 4% 14% 7% 44% 8% 19% 62% 11% 12% Arthroplasty Critical Care & General Medicine Self Pay Corporate Government TPA Corporate Private Cardiac Science Oncology Other Ortho Neurology Nephrology Others 11
Slide 13: Surgery Count and Cost Structure Q2FY19
Surgery Count and Cost Structure Q2FY19 Cost Structure Surgery Count 14% 79% 3% 5% 1% 4% 18% 45% 3% 6% 27% 7% 25% 7% Q2FY19 14% Total Cost Advertising and Promotion Arthroplasty Other Ortho Nephrology Administrative Expenses Employee Cost Gynecology & IVF General Surgery Cardiac Science Other Operat
Slide 14: Bed Count Split
Bed Count Split 2,012 2,012 1,102 941 452 318 Q2 FY18 Q2 FY19 Bed Capacity Operational Occupied • Increase in occupancy by 42% on Year on Year basis reflects better utilization of increased operational capacity and ramp up of newly established units. 13
Slide 15: Maturity Profile – Q2FY19
Maturity Profile – Q2FY19 Avg. Operational Non- Non-Census Total Bed Maturity Profile Occupied Census Beds Beds Operational Beds Capacity Beds Beds 4 years + (SG; Vijay; 178 325 57 382 212 594 Krishna; Vapi) 2-4 years (Jabalpur, 157 309 52 361 115 476 Indore) < 2 years (Jaipur; Naroda; 117 583 892 2
Slide 16: Maturity Profile – Q2FY19 – with Revenue mix
Maturity Profile – Q2FY19 – with Revenue mix % of Total Maturity Profile Arthroplasty Non Arthroplasty ALOS Revenue 4 years + (SG; Vijay; 20% Krishna; Vapi) 50% 29% 3.37 2-4 years 4% 19% 3.75 (Jabalpur, Indore) 23% < 2 years 27% (Jaipur; Naroda; Surat; Mohali) 11% 17% 1.79 Total 100% 44% 56% 2.82 15
Slide 17: Maturity Profile – Q2FY19 vs Q2 FY18 – Operational Parameters
Maturity Profile – Q2FY19 vs Q2 FY18 – Operational Parameters Q2 FY 19 Q2 FY 18 Maturity Profile IP Count OP Count Surgery Count Maturity Profile IP Count OP Count Surgery Count 4 years + 4 years + (SG; Vijay; 4,851 29,474 2,506 (SG; Vijay; 4,085 28,009 2,763 Krishna; Vapi) Krishna; Vapi) 2-4 years
Slide 18: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th September 2018 0.94% 0.28% 0.42% Promoter & Promoter 0.91% 0.08% Group 0.04% Resident Individual & HUF 4.02% Foreign Portfolio Investors 5.85% Bodies Corporates 8.05% Alternative Investment Fund Shalby Medicos Trust Mutual Funds Non Resident Indians / For
Slide 19: Our Strengths and Differentiators
Our Strengths and Differentiators Strong brand, Increasing focus Experienced global Optimized on Quaternary promoters with leadership in Business Model treatments such hands-on Joint now being as Oncology and involvement Replacement replicated Organ transplants Even after the Strong emphasis Leaders
Slide 20: Detailed Information
Detailed Information For more detailed information please click on the link below: • Q2FY19 result • Q1FY19 result • Monitoring Agency Report for IPO proceeds • FY18 result 19
Slide 21: Thank you
Thank you SHALBY LIMITED Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3120 | Website: www.shalby.org | CIN: L85110GJ2004PLC044667 Script code: BSE: 540797 | NSE: SHALBY